Hallstrom I P, Liao D Z, Assefaw-Redda Y, Ohlson L C, Sahlin L, Eneroth P, Eriksson L C, Gustafsson J A, Blanck A
Department of Medical Nutrition, NOVUM, Huddinge University Hospital, Sweden.
Hepatology. 1996 Oct;24(4):849-54. doi: 10.1002/hep.510240416.
Synthetic estrogens act as tumor promoters in rat liver. Because estrogen treatment markedly increases the secretion of pituitary prolactin, also shown to be a tumor promoter in rat liver, the possibility of a pituitary influence in estrogen promotion was investigated in Wistar rats. In diethylnitrosamine (DEN)-initiated hypophysectomized (hx) female rats, 24 weeks of ethinyl estradiol (EE) administration (500 microg/kg/d, intraperitoneally) did not increase the number of hepatocyte nodules and did not induce hepatocellular carcinoma (HCC) in a 2-year study. Very few placental forms of glutathione-S-transferase (GST-P)-positive foci were observed at the end of EE administration. Estrogen receptor (ER) messenger RNA (mRNA) levels in hx females were 20% of the levels in intact females. EE administration (range, 160-210 microg/kg/d, subcutaneous release pellets) to DEN-initiated intact males and females increased the number and size of hepatocyte foci. A significant increase in HCC frequency was observed in EE-treated females compared with females receiving sham-release pellets, and the latency period for HCC induction was decreased by EE in both males and females. Inhibition of prolactin (PRL) secretion by bromocriptine (Brc) (ParlodelLAR, slow intramuscular release vehicles) during EE treatment decreased the number of foci without affecting their size and markedly prolonged the latency period in both sexes. EE treatment also significantly increased the expression of c-myc, and c-jun, enhanced the levels of growth hormone receptor (GHr) mRNA in females and the levels of ER mRNA in males and "feminized" the expression of the GH-regulated genes cytochrome P450 (CYP), 2C11, CYP 2C12, and GHr in male liver. Brc administration decreased the mRNA levels of the female-predominant CYP 2C12 in EE-treated males but otherwise had no effects. In conclusion, a decreased promotive effect of EE was obtained by decreasing the PRL levels, indicating that estrogens exert at least part of their promotion effects indirectly, by increasing the levels of pituitary PRL.
合成雌激素在大鼠肝脏中起肿瘤促进剂的作用。由于雌激素治疗可显著增加垂体催乳素的分泌,而垂体催乳素在大鼠肝脏中也被证明是一种肿瘤促进剂,因此在Wistar大鼠中研究了垂体对雌激素促进作用的影响。在二乙基亚硝胺(DEN)引发的垂体切除(hx)雌性大鼠中,在一项为期2年的研究中,给予乙炔雌二醇(EE)24周(500微克/千克/天,腹腔注射)并未增加肝细胞结节的数量,也未诱发肝细胞癌(HCC)。在EE给药结束时,仅观察到极少量胎盘形式的谷胱甘肽-S-转移酶(GST-P)阳性病灶。hx雌性大鼠中的雌激素受体(ER)信使核糖核酸(mRNA)水平为完整雌性大鼠的20%。对DEN引发的完整雄性和雌性大鼠皮下植入释放丸剂给予EE(剂量范围为160 - 210微克/千克/天),增加了肝细胞病灶的数量和大小。与接受假释放丸剂的雌性大鼠相比,EE处理的雌性大鼠中HCC发生率显著增加,并且EE缩短了雄性和雌性大鼠诱发HCC的潜伏期。在EE治疗期间,用溴隐亭(Brc)(ParlodelLAR,缓慢肌肉内释放载体)抑制催乳素(PRL)分泌可减少病灶数量,但不影响其大小,并且显著延长了两性的潜伏期。EE治疗还显著增加了c-myc和c-jun的表达,提高了雌性大鼠生长激素受体(GHr)mRNA水平以及雄性大鼠ER mRNA水平,并使雄性肝脏中生长激素调节基因细胞色素P450(CYP)2C11、CYP 2C12和GHr的表达“女性化”。Brc给药降低了EE处理的雄性大鼠中以雌性为主的CYP 2C12的mRNA水平,但其他方面无影响。总之,通过降低PRL水平获得了EE促进作用的减弱,这表明雌激素至少部分通过增加垂体PRL水平间接发挥其促进作用。